Literature DB >> 25512402

Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.

Ping Ren1, Ming Luo2, Shao Lin2, Mahmoud A Ghannoum3, Nancy Isham3, Dan J Diekema4, Michael A Pfaller4, Shawn Messer4, Shawn R Lockhart5, Naureen Iqbal5, Vishnu Chaturvedi6.   

Abstract

Four laboratories tested three isolates of Candida species and two isolates of Aspergillus fumigatus using 96-well plates containing combinations of amphotericin B, anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole. The majority of summation fractional inhibitory concentration indices (ΣFICI) based on the Lowe additivity formula suggested indifferent drug interactions (ΣFICI > 0.5 and ≤4.0) and no instance of drug antagonism (ΣFICI > 4.0). The intra- and interlaboratory agreement rates were superior when MIC100 readings were used as endpoints (at a 99% confidence interval [CI]).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25512402      PMCID: PMC4325810          DOI: 10.1128/AAC.04545-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Combinations of antifungal agents in therapy--what value are they?

Authors:  Manuel Cuenca-Estrella
Journal:  J Antimicrob Chemother       Date:  2004-09-16       Impact factor: 5.790

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-01-11       Impact factor: 8.067

4.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

5.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Authors:  Dimitrios P Kontoyiannis; Kieren A Marr; Benjamin J Park; Barbara D Alexander; Elias J Anaissie; Thomas J Walsh; James Ito; David R Andes; John W Baddley; Janice M Brown; Lisa M Brumble; Alison G Freifeld; Susan Hadley; Loreen A Herwaldt; Carol A Kauffman; Katherine Knapp; G Marshall Lyon; Vicki A Morrison; Genovefa Papanicolaou; Thomas F Patterson; Trish M Perl; Mindy G Schuster; Randall Walker; Kathleen A Wannemuehler; John R Wingard; Tom M Chiller; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

6.  Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.

Authors:  Joseph Meletiadis; Paul E Verweij; Debbie T A TeDorsthorst; Jacques F G M Meis; Johan W Mouton
Journal:  Med Mycol       Date:  2005-03       Impact factor: 4.076

7.  Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study.

Authors:  Marya D Zilberberg; Marin H Kollef; Heather Arnold; Andrew Labelle; Scott T Micek; Smita Kothari; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2010-06-03       Impact factor: 3.090

8.  Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

9.  Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

Authors:  Vishnu Chaturvedi; Rama Ramani; Mahmoud A Ghannoum; Scott B Killian; Nicole Holliday; Cindy Knapp; Luis Ostrosky-Zeichner; Shawn A Messer; Michael A Pfaller; Naureen J Iqbal; Beth A Arthington-Skaggs; Jose A Vazquez; Tin Sein; John H Rex; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

10.  Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.

Authors:  A Candoni; M Caira; S Cesaro; A Busca; M Giacchino; R Fanci; M Delia; A Nosari; A Bonini; C Cattaneo; L Melillo; C Caramatti; G Milone; R Scime'; M Picardi; R Fanin; L Pagano
Journal:  Mycoses       Date:  2013-12-23       Impact factor: 4.377

View more
  5 in total

1.  In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.

Authors:  Brittany O'Brien; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.

Authors:  Samantha E Jacobs; Jonathan L Jacobs; Emily K Dennis; Sarah Taimur; Meenakshi Rana; Dhruv Patel; Melissa Gitman; Gopi Patel; Sarah Schaefer; Kishore Iyer; Jang Moon; Victoria Adams; Polina Lerner; Thomas J Walsh; YanChun Zhu; Mohammed Rokebul Anower; Mayuri M Vaidya; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2022-06-30       Impact factor: 5.938

Review 4.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

5.  Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris.

Authors:  Sergio A Alanís-Ríos; Gloria M González; Angel Andrade; Miguel A Becerril-García; Alexandro Bonifaz; Efrén R Robledo-Leal; Alexandra M Montoya; Rogelio de J Treviño-Rangel
Journal:  Braz J Microbiol       Date:  2022-08-29       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.